{"id":"albuterol-salbutamol-mdi","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Nervousness or anxiety"},{"rate":"3-5%","effect":"Headache"},{"rate":"1-5%","effect":"Palpitations"},{"rate":"1-3%","effect":"Muscle cramps"},{"rate":"1-5%","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and airway dilation, rapidly relieving bronchoconstriction. The metered-dose inhaler (MDI) formulation delivers the drug directly to the lungs for quick onset of action.","oneSentence":"Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:53.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm and reversible airway obstruction in asthma"},{"name":"Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction"},{"name":"Exercise-induced bronchoconstriction prevention"}]},"trialDetails":[{"nctId":"NCT01799538","phase":"PHASE1, PHASE2","title":"Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-06-10","conditions":"Lymphangioleiomyomatosis","enrollment":100},{"nctId":"NCT06471257","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-17","conditions":"Asthma","enrollment":790},{"nctId":"NCT07037511","phase":"NA","title":"Effects of Salbutamol in Athletes and Implications for Screening and Sports","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-10-30","conditions":"Asthma, Healthy, Effect of Drug","enrollment":64},{"nctId":"NCT06307665","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-20","conditions":"Asthma","enrollment":440},{"nctId":"NCT06563102","phase":"PHASE4","title":"Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-11","conditions":"Mild Asthma","enrollment":101},{"nctId":"NCT06261957","phase":"PHASE3","title":"A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-31","conditions":"Asthma","enrollment":477},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":"Asthma","enrollment":422},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT06433908","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-06-04","conditions":"Asthma, Healthy Participants","enrollment":60},{"nctId":"NCT06422689","phase":"PHASE4","title":"Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-05-10","conditions":"Asthma","enrollment":1507},{"nctId":"NCT06433921","phase":"PHASE1","title":"A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-14","conditions":"Asthma, Mild Asthma","enrollment":84},{"nctId":"NCT05366764","phase":"PHASE1","title":"First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-06-08","conditions":"Asthma","enrollment":36},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":"Primary Ciliary Dyskinesia","enrollment":27},{"nctId":"NCT06644924","phase":"PHASE2","title":"A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-02-10","conditions":"Asthma","enrollment":118},{"nctId":"NCT06245551","phase":"PHASE3","title":"A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-22","conditions":"Asthma, Exercise-Induced","enrollment":64},{"nctId":"NCT06514157","phase":"PHASE1","title":"Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-19","conditions":"Healthy Volunteer","enrollment":14},{"nctId":"NCT05505734","phase":"PHASE3","title":"A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2022-09-02","conditions":"Asthma","enrollment":2516},{"nctId":"NCT06154304","phase":"PHASE3","title":"BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2023-12-06","conditions":"Bronchial Asthma","enrollment":120},{"nctId":"NCT05819541","phase":"PHASE2","title":"Treating Exacerbations of Asthma With Oral Montelukast in Children","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-20","conditions":"Status Asthmaticus","enrollment":90},{"nctId":"NCT05035862","phase":"PHASE1","title":"Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma","status":"TERMINATED","sponsor":"Emory University","startDate":"2022-03-16","conditions":"Asthma","enrollment":1},{"nctId":"NCT06655012","phase":"NA","title":"Salmeterol Effect on Exercise Performance","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT06654986","phase":"NA","title":"Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT03522831","phase":"NA","title":"CF Bronchodilation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2018-05-01","conditions":"Lung Diseases, Cystic Fibrosis","enrollment":20},{"nctId":"NCT06201156","phase":"NA","title":"Comparison of Nebulizers vs Metered-Dose Inhalers With Spacer Device For Treatment Of Childhood Wheeze","status":"COMPLETED","sponsor":"Khyber Teaching Hospital","startDate":"2023-12-10","conditions":"Childhood Asthma With Acute Exacerbation","enrollment":160},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT06816342","phase":"PHASE4","title":"Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs","status":"RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-11-01","conditions":"Asthmatic Patients, MDI, Aerosol Generating Procedure","enrollment":120},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":"Airway Inflammation, Asthma","enrollment":42},{"nctId":"NCT04276233","phase":"PHASE4","title":"Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-29","conditions":"Asthma","enrollment":100},{"nctId":"NCT05977699","phase":"PHASE4","title":"Reversibility of Methacholine Induced Bronchoconstriction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2024-01-12","conditions":"Asthma","enrollment":20},{"nctId":"NCT04914273","phase":"NA","title":"Use of Exhaled Particles to Assess Lung Pharmacokinetics","status":"COMPLETED","sponsor":"Fraunhofer-Institute of Toxicology and Experimental Medicine","startDate":"2021-06-14","conditions":"Healthy, Lung Pharmacokinetic","enrollment":6},{"nctId":"NCT06618105","phase":"PHASE3","title":"Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd","status":"NOT_YET_RECRUITING","sponsor":"Macleods Pharmaceuticals Ltd","startDate":"2024-10-15","conditions":"Mild Asthma","enrollment":144},{"nctId":"NCT05791565","phase":"PHASE1","title":"Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-04-03","conditions":"Asthma","enrollment":28},{"nctId":"NCT03562195","phase":"PHASE3","title":"A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-29","conditions":"Asthma","enrollment":300},{"nctId":"NCT00070707","phase":"PHASE4","title":"Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-03","conditions":"Rhinitis, Allergic, Seasonal, Asthma","enrollment":188},{"nctId":"NCT05363670","phase":"PHASE2","title":"Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma","status":"COMPLETED","sponsor":"ARS Pharmaceuticals, Inc.","startDate":"2022-07-28","conditions":"Asthma","enrollment":18},{"nctId":"NCT06139991","phase":"PHASE1","title":"Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-16","conditions":"Heathy Participants","enrollment":66},{"nctId":"NCT01471340","phase":"PHASE4","title":"A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-01-09","conditions":"Asthma","enrollment":11744},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT02741271","phase":"PHASE3","title":"Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-11","conditions":"Asthma","enrollment":181},{"nctId":"NCT04803734","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2021-03-19","conditions":"Healthy","enrollment":60},{"nctId":"NCT05300087","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2022-02-24","conditions":"Healthy","enrollment":60},{"nctId":"NCT06271408","phase":"PHASE1","title":"Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging","status":"UNKNOWN","sponsor":"Polarean, Inc.","startDate":"2024-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":6},{"nctId":"NCT00388882","phase":"PHASE4","title":"Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-10-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":327},{"nctId":"NCT05428956","phase":"NA","title":"Two Inhalation Methods Using a Pressurized Metered Dose Inhaler With Valved Holding Chamber to Assess Improvement in Lung Function After SABA Administration in Bronchial Asthma","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-06-15","conditions":"Bronchial Asthma","enrollment":897},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT06040424","phase":"PHASE3","title":"Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2023-09-28","conditions":"COPD","enrollment":74},{"nctId":"NCT05084222","phase":"PHASE4","title":"Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-11-11","conditions":"Asthma","enrollment":180},{"nctId":"NCT03847896","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2019-03-20","conditions":"Asthma","enrollment":1001},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT01721291","phase":"PHASE4","title":"Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-10-01","conditions":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, HEALTHY SUBJECTS","enrollment":65},{"nctId":"NCT01470755","phase":"PHASE2","title":"Study of Dose-response to Bronchodilator and Dose-finding in Child 2.5 to 6 Years - Study Golden","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-01","conditions":"Asthma","enrollment":90},{"nctId":"NCT03769090","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2018-12-13","conditions":"Asthma","enrollment":3132},{"nctId":"NCT00530062","phase":"PHASE4","title":"Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-07-25","conditions":"Asthma","enrollment":49},{"nctId":"NCT02232087","phase":"PHASE1","title":"Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2014-07","conditions":"Healthy","enrollment":52},{"nctId":"NCT04848662","phase":"PHASE1","title":"To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2021-05-06","conditions":"Asthma","enrollment":12},{"nctId":"NCT04402658","phase":"NA","title":"Can Anti-asthmatic Medication Improve Sprint Performance in Healthy Endurance Athletes?","status":"WITHDRAWN","sponsor":"Norwegian School of Sport Sciences","startDate":"2022-08-01","conditions":"Sports Drug Abuse","enrollment":""},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT04681079","phase":"","title":"Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2021-05-04","conditions":"COVID-19","enrollment":14},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT04234464","phase":"PHASE3","title":"A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2020-01-15","conditions":"Exercise Induced Bronchospasm","enrollment":60},{"nctId":"NCT05152355","phase":"PHASE4","title":"Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2019-04-22","conditions":"Asthma","enrollment":270},{"nctId":"NCT00054964","phase":"PHASE2","title":"Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2003-03-31","conditions":"Asthma","enrollment":14},{"nctId":"NCT00085774","phase":"PHASE3","title":"Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-06-30","conditions":"Exercise-induced Bronchospasm","enrollment":24},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT04446637","phase":"PHASE3","title":"Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD","status":"WITHDRAWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2021-09-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03345407","phase":"PHASE2","title":"Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":943},{"nctId":"NCT03380429","phase":"PHASE4","title":"A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-01-31","conditions":"Asthma","enrollment":437},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT02584257","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2016-04","conditions":"Mild Persistent Asthma","enrollment":217},{"nctId":"NCT03357341","phase":"","title":"Sensor and Electronic Health Records (EHR) Integration Pilot Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":194},{"nctId":"NCT04615611","phase":"NA","title":"Physiologic Performance Response to Salbutamol","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2020-11-07","conditions":"Healthy","enrollment":20},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT03170232","phase":"PHASE2","title":"A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-10-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT00388739","phase":"NA","title":"Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2006-11-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT03184987","phase":"PHASE3","title":"A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-22","conditions":"Asthma","enrollment":111},{"nctId":"NCT00440245","phase":"PHASE4","title":"Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2007-02","conditions":"Asthma, COPD","enrollment":28},{"nctId":"NCT03934333","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-05-16","conditions":"Relative Bioavailability","enrollment":11},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT02654145","phase":"PHASE4","title":"Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-17","conditions":"Asthma","enrollment":145},{"nctId":"NCT02624505","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2015-12","conditions":"Bronchial Asthma","enrollment":110},{"nctId":"NCT03364608","phase":"PHASE2","title":"Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT03371459","phase":"PHASE2","title":"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-29","conditions":"Asthma","enrollment":46},{"nctId":"NCT03369847","phase":"PHASE4","title":"Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge","status":"COMPLETED","sponsor":"New York City Health and Hospitals Corporation","startDate":"2017-09-10","conditions":"Asthma, Pediatric ALL","enrollment":43},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT02794480","phase":"PHASE4","title":"Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-22","conditions":"Asthma","enrollment":324},{"nctId":"NCT02499887","phase":"NA","title":"Repeat Emergency Department Visits Among Patients With Asthma and COPD","status":"TERMINATED","sponsor":"State University of New York at Buffalo","startDate":"2016-01","conditions":"Asthma, COPD","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Albuterol/salbutamol MDI","genericName":"Albuterol/salbutamol MDI","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation. Used for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction, Exercise-induced bronchoconstriction prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}